;PMID: 10839294
;source_file_2938.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..165] = [t:43..165]
;2)section:[e:169..260] = [t:169..260]
;3)section:[e:264..352] = [t:264..352]
;4)sentence:[e:356..486] = [t:356..486]
;5)sentence:[e:487..700] = [t:487..700]
;6)sentence:[e:701..873] = [t:701..873]
;7)sentence:[e:874..938] = [t:874..938]
;8)sentence:[e:939..999] = [t:939..999]
;9)sentence:[e:1000..1141] = [t:1000..1141]
;10)sentence:[e:1142..1329] = [t:1142..1329]
;11)sentence:[e:1330..1443] = [t:1330..1443]
;12)section:[e:1447..1492] = [t:1447..1492]

;section 0 Span:0..37
;Br J Cancer.  2000 Jun;82(11):1801-7.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..11] Cancer) (.:[11..12] .)
        (CD:[14..18] 2000) (CC:[19..25] Jun;82) (-LRB-:[25..26] -LRB-)
        (CD:[26..28] 11) (-RRB-:[28..29] -RRB-) (::[29..30] :)
        (CD:[30..34] 1801) (HYPH:[34..35] -) (CD:[35..37] 7.)))

;sentence 1 Span:43..165
;Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma 
;defines a 1.1-Mb region of common allelic loss.
;[88..93]:variation-location:"14q32"
;[103..116]:malignancy-type:"neuroblastoma"
;[152..164]:variation-type:"allelic loss"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (JJ:[43..51] Detailed) (NN:[52..60] deletion) (NN:[61..68] mapping))
      (PP (IN:[69..71] of)
        (NP (NN:[72..82] chromosome) (NN:[83..87] band) (NN:[88..93] 14q32)))
      (PP (IN:[94..96] in)
        (NP (JJ:[97..102] human) (NN:[103..116] neuroblastoma))))
    (VP (VBZ:[118..125] defines)
      (NP
        (NP (DT:[126..127] a)
          (NML (CD:[128..131] 1.1) (HYPH:[131..132] -) (NN:[132..134] Mb))
          (NN:[135..141] region))
        (PP (IN:[142..144] of)
          (NP (JJ:[145..151] common)
             (JJ:[152..159] allelic) (NN:[160..164] loss)))))
    (.:[164..165] .)))

;section 2 Span:169..260
;Hoshi M, Otagiri N, Shiwaku HO, Asakawa S, Shimizu N, Kaneko Y, Ohi R,
;Hayashi  Y, Horii A.
(SEC
  (FRAG (NNP:[169..174] Hoshi) (NNP:[175..177] M,) (NNP:[178..185] Otagiri)
        (NNP:[186..187] N) (,:[187..188] ,) (NNP:[189..196] Shiwaku)
        (NN:[197..199] HO) (,:[199..200] ,) (NNP:[201..208] Asakawa)
        (NNP:[209..210] S) (,:[210..211] ,) (NNP:[212..219] Shimizu)
        (NNP:[220..221] N) (,:[221..222] ,) (NNP:[223..229] Kaneko)
        (NNP:[230..231] Y) (,:[231..232] ,) (NNP:[233..236] Ohi)
        (NNP:[237..238] R) (,:[238..239] ,) (NNP:[240..247] Hayashi)
        (NNP:[249..250] Y) (,:[250..251] ,) (NNP:[252..257] Horii)
        (NNP:[258..259] A) (.:[259..260] .)))

;section 3 Span:264..352
;Department of Molecular Pathology, Tohoku University School of Medicine,
;Sendai,  Japan.
(SEC
  (FRAG (NNP:[264..274] Department) (IN:[275..277] of)
        (NNP:[278..287] Molecular) (NNP:[288..297] Pathology) (,:[297..298] ,)
        (NNP:[299..305] Tohoku) (NNP:[306..316] University)
        (NNP:[317..323] School) (IN:[324..326] of) (NNP:[327..335] Medicine)
        (,:[335..336] ,) (NNP:[337..343] Sendai) (,:[343..344] ,)
        (NNP:[346..351] Japan) (.:[351..352] .)))

;sentence 4 Span:356..486
;Neuroblastoma (NB) is a well-known malignant disease in infants, but its 
;molecular mechanisms have not yet been fully elucidated.
;[356..369]:malignancy-type:"Neuroblastoma"
;[371..373]:malignancy-type:"NB"
;[391..400]:malignancy-clinical-stage:"malignant"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[356..369] Neuroblastoma))
        (NP (-LRB-:[370..371] -LRB-) (NN:[371..373] NB) (-RRB-:[373..374] -RRB-)))
      (VP (VBZ:[375..377] is)
        (NP-PRD (DT:[378..379] a)
          (ADJP (RB:[380..384] well) (HYPH:[384..385] -) (VBN:[385..390] known))
          (JJ:[391..400] malignant) (NN:[401..408] disease))
        (PP (IN:[409..411] in)
          (NP (NNS:[412..419] infants)))))
    (,:[419..420] ,) (CC:[421..424] but)
    (S
      (NP-SBJ-1 (PRP$:[425..428] its) (JJ:[430..439] molecular)
                (NNS:[440..450] mechanisms))
      (VP (VBP:[451..455] have) (RB:[456..459] not)
        (ADVP (RB:[460..463] yet))
        (VP (VBN:[464..468] been)
          (ADVP (RB:[469..474] fully))
          (VP (VBN:[475..485] elucidated)
            (NP-1 (-NONE-:[485..485] *))))))
    (.:[485..486] .)))

;sentence 5 Span:487..700
;To investigate the  genetic contribution of abnormalities on the long arm of
;chromosome 14 (14q) in  NB, we analysed loss of heterozygosity (LOH) in 54
;primary NB samples using 12  microsatellite markers on 14q32.
;[552..577]:variation-location:"long arm of chromosome 14"
;[579..582]:variation-location:"14q"
;[588..590]:malignancy-type:"NB"
;[604..626]:variation-type:"loss of heterozygosity"
;[628..631]:variation-type:"LOH"
;[639..646]:malignancy-clinical-stage:"primary"
;[647..649]:malignancy-type:"NB"
;[694..699]:variation-location:"14q32"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[487..487] *))
      (VP (TO:[487..489] To)
        (VP (VB:[490..501] investigate)
          (NP
            (NP (DT:[502..505] the) (JJ:[507..514] genetic)
                (NN:[515..527] contribution))
            (PP (IN:[528..530] of)
              (NP
                (NP (NNS:[531..544] abnormalities))
                (PP (IN:[545..547] on)
                  (NP
                    (NP (DT:[548..551] the) (JJ:[552..556] long)
                        (NN:[557..560] arm))
                    (PP (IN:[561..563] of)
                      (NP (NN:[564..574] chromosome) (CD:[575..577] 14)))
                    (PRN (-LRB-:[578..579] -LRB-)
                      (NP (NN:[579..582] 14q))
                      (-RRB-:[582..583] -RRB-))))))
            (PP (IN:[584..586] in)
              (NP (NN:[588..590] NB)))))))
    (,:[590..591] ,)
    (NP-SBJ (PRP:[592..594] we))
    (VP (VBD:[595..603] analysed)
      (NP
        
        (NP (NN:[604..608] loss))
        (PP (IN:[609..611] of)
          (NP (NN:[612..626] heterozygosity)))
        (PRN (-LRB-:[627..628] -LRB-)
          (NP (NN:[628..631] LOH))
          (-RRB-:[631..632] -RRB-)))
      (PP (IN:[633..635] in)
        (NP (CD:[636..638] 54) (JJ:[639..646] primary) (NN:[647..649] NB)
            (NNS:[650..657] samples)))
      (S-MNR
        (NP-SBJ (-NONE-:[657..657] *))
        (VP (VBG:[658..663] using)
          (NP
            (NP (CD:[664..666] 12) (NN:[668..682] microsatellite)
                (NNS:[683..690] markers))
            (PP (IN:[691..693] on)
              (NP (NN:[694..699] 14q32)))))))
    (.:[699..700] .)))

;sentence 6 Span:701..873
;Seventeen (31%) of 54 tumours showed LOH at one  or more of the markers
;analysed, and the smallest common region of allelic loss  was identified
;between D14S62 and D14S987.
;[738..741]:variation-type:"LOH"
;[817..829]:variation-type:"allelic loss"
;[846..872]:variation-location:"between D14S62 and D14S987"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (CD:[701..710] Seventeen)
          (PRN (-LRB-:[711..712] -LRB-)
            (NP (CD:[712..714] 31) (NN:[714..715] %))
            (-RRB-:[715..716] -RRB-)))
        (PP (IN:[717..719] of)
          (NP (CD:[720..722] 54) (NNS:[723..730] tumours))))
      (VP (VBD:[731..737] showed)
        (NP (NN:[738..741] LOH))
        (PP-LOC (IN:[742..744] at)
          (NP
            (NP
              (QP (CD:[745..748] one) (CC:[750..752] or) (JJR:[753..757] more)))
            (PP (IN:[758..760] of)
              (NP
                (NP (DT:[761..764] the) (NNS:[765..772] markers))
                (VP (VBN:[773..781] analysed)
                  (NP (-NONE-:[781..781] *)))))))))
    (,:[781..782] ,) (CC:[783..786] and)
    (S
      (NP-SBJ-1
        (NP (DT:[787..790] the) (JJS:[791..799] smallest) (JJ:[800..806] common)
            (NN:[807..813] region))
        (PP (IN:[814..816] of)
          (NP (JJ:[817..824] allelic) (NN:[825..829] loss))))
      (VP (VBD:[831..834] was)
        (VP (VBN:[835..845] identified)
          (NP-1 (-NONE-:[845..845] *))
          (PP (IN:[846..853] between)
            (NP (NN:[854..860] D14S62) (CC:[861..864] and)
                (NN:[865..872] D14S987))))))
    (.:[872..873] .)))

;sentence 7 Span:874..938
;This region was estimated to be 1-cM  long from the linkage map.
(SENT
  (S
    (NP-SBJ-1 (DT:[874..878] This) (NN:[879..885] region))
    (VP (VBD:[886..889] was)
      (VP (VBN:[890..899] estimated)
        (S
          (NP-SBJ-1 (-NONE-:[899..899] *))
          (VP (TO:[900..902] to)
            (VP (VB:[903..905] be)
              (ADJP-PRD
                (NML (CD:[906..907] 1) (HYPH:[907..908] -) (NN:[908..910] cM))
                (JJ:[912..916] long)))))
        (PP (IN:[917..921] from)
          (NP (DT:[922..925] the) (NN:[926..933] linkage) (NN:[934..937] map)))))
    (.:[937..938] .)))

;sentence 8 Span:939..999
;Fluorescence in situ hybridization also confirmed the  loss.
;[994..998]:variation-type:"loss"
(SENT
  (S
    (NP-SBJ (NN:[939..951] Fluorescence)
      (NML (FW:[952..954] in) (FW:[955..959] situ))
      (NN:[960..973] hybridization))
    (ADVP (RB:[974..978] also))
    (VP (VBD:[979..988] confirmed)
      (NP (DT:[989..992] the) (NN:[994..998] loss)))
    (.:[998..999] .)))

;sentence 9 Span:1000..1141
;There was no statistical correlation between LOH and any clinicopathologic 
;features, including age, stage, amplification of MYCN and ploidy.
;[1045..1048]:variation-type:"LOH"
;[1108..1121]:variation-type:"amplification"
;[1125..1129]:gene-rna:"MYCN"
(SENT
  (S
    (NP-SBJ (EX:[1000..1005] There))
    (VP (VBD:[1006..1009] was)
      (NP-PRD
        (NP (DT:[1010..1012] no) (JJ:[1013..1024] statistical)
            (NN:[1025..1036] correlation))
        (PP (IN:[1037..1044] between)
          (NP
            (NP (NN:[1045..1048] LOH))
            (CC:[1049..1052] and)
            (NP
              (NP (DT:[1053..1056] any) (JJ:[1057..1074] clinicopathologic)
                  (NNS:[1076..1084] features))
              (,:[1084..1085] ,)
              (PP (VBG:[1086..1095] including)
                (NP
                  (NP (NN:[1096..1099] age))
                  (,:[1099..1100] ,)
                  (NP (NN:[1101..1106] stage))
                  (,:[1106..1107] ,)
                  (NP
                    (NP (NN:[1108..1121] amplification))
                    (PP (IN:[1122..1124] of)
                      (NP (NN:[1125..1129] MYCN))))
                  (CC:[1130..1133] and)
                  (NP (NN:[1134..1140] ploidy)))))))))
    (.:[1140..1141] .)))

;sentence 10 Span:1142..1329
;We further  constructed a contig spanning the lost region using bacterial
;artificial  chromosome and estimated this region to be approximately 1.1-Mb
;by pulsed-field  gel electrophoresis.
(SENT
  (S
    (NP-SBJ (PRP:[1142..1144] We))
    (ADVP (RB:[1145..1152] further))
    (VP
      (VP (VBD:[1154..1165] constructed)
        (NP
          (NP (DT:[1166..1167] a) (NN:[1168..1174] contig))
          (VP (VBG:[1175..1183] spanning)
            (NP (DT:[1184..1187] the) (VBN:[1188..1192] lost)
                (NN:[1193..1199] region))))
        (S-MNR
          (NP-SBJ (-NONE-:[1199..1199] *))
          (VP (VBG:[1200..1205] using)
            (NP (JJ:[1206..1215] bacterial) (JJ:[1216..1226] artificial)
                (NN:[1228..1238] chromosome)))))
      (CC:[1239..1242] and)
      (VP (VBD:[1243..1252] estimated)
        (S
          (NP-SBJ (DT:[1253..1257] this) (NN:[1258..1264] region))
          (VP (TO:[1265..1267] to)
            (VP (VB:[1268..1270] be)
              (NP-PRD
                (QP (RB:[1271..1284] approximately) (CD:[1285..1288] 1.1))
                (HYPH:[1288..1289] -) (NN:[1289..1291] Mb)))))
        (PP (IN:[1292..1294] by)
          (NP
            (NML (VBN:[1295..1301] pulsed) (HYPH:[1301..1302] -)
                 (NN:[1302..1307] field))
            (NN:[1309..1312] gel) (NN:[1313..1328] electrophoresis)))))
    (.:[1328..1329] .)))

;sentence 11 Span:1330..1443
;Our results will contribute to cloning and characterizing  the putative
;tumour-associated gene(s) in 14q32 in NB.
;[1431..1436]:variation-location:"14q32"
;[1440..1442]:malignancy-type:"NB"
(SENT
  (S
    (NP-SBJ (PRP$:[1330..1333] Our) (NNS:[1334..1341] results))
    (VP (MD:[1342..1346] will)
      (VP (VB:[1347..1357] contribute)
        (PP (TO:[1358..1360] to)
          (S-NOM
            (NP-SBJ (-NONE-:[1360..1360] *))
            (VP (VBG:[1361..1368] cloning) (CC:[1369..1372] and)
                (VBG:[1373..1387] characterizing)
              (NP
                (NP (DT:[1389..1392] the) (JJ:[1393..1401] putative)
                  (ADJP (NN:[1402..1408] tumour) (HYPH:[1408..1409] -)
                        (VBN:[1409..1419] associated))
                  (NN:[1420..1427] gene-LRB-s-RRB-))
                (PP (IN:[1428..1430] in)
                  (NP (NN:[1431..1436] 14q32)))
                (PP (IN:[1437..1439] in)
                  (NP (NN:[1440..1442] NB)))))))))
    (.:[1442..1443] .)))

;section 12 Span:1447..1492
;PMID: 10839294 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1447..1451] PMID) (::[1451..1452] :) (CD:[1453..1461] 10839294)
        (NN:[1462..1463] -LSB-) (NNP:[1463..1469] PubMed) (::[1470..1471] -)
        (NN:[1472..1479] indexed) (IN:[1480..1483] for)
        (NNP:[1484..1492] MEDLINE-RSB-)))
